ANALGESIC AND MUSCLE RELAXANT CAPLETS TABLET

מדינה: קנדה

שפה: אנגלית

מקור: Health Canada

מרכיב פעיל:

IBUPROFEN; METHOCARBAMOL

זמין מ:

TEVA CANADA LIMITED

קוד ATC:

M03BA53

INN (שם בינלאומי):

METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS

כמות:

200MG; 500MG

טופס פרצבטיות:

TABLET

הרכב:

IBUPROFEN 200MG; METHOCARBAMOL 500MG

מסלול נתינה (של תרופות):

ORAL

יחידות באריזה:

18/40

סוג מרשם:

OTC

איזור תרפויטי:

CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS

leaflet_short:

Active ingredient group (AIG) number: 0248961001; AHFS:

מצב אישור:

CANCELLED POST MARKET

תאריך אישור:

2021-08-12

מאפייני מוצר

1 | P a g e
PRODUCT MONOGRAPH
ANALGESIC & MUSCLE RELAXANT CAPLETS
500 MG METHOCARBAMOL AND 200 MG IBUPROFEN TABLETS
THERAPEUTIC CLASSIFICATION
MUSCLE RELAXANT / ANALGESIC
TEVA CANADA LIMITED
Date of Preparation:
30 Novopharm Court
January 8, 2013
Toronto, Canada
M1B 2K9
Control# 161025
2 | P a g e
TABLE OF CONTENTS
Clinical Pharmacology
..............................................................................................................................
3
Indications:
................................................................................................................................................
7
Contraindications
......................................................................................................................................
8
Warnings:
..................................................................................................................................................
8
Precautions
..............................................................................................................................................
12
Drug Interactions
....................................................................................................................................
13
Adverse Reactions
..................................................................................................................................
15
Symptoms and Treatment of Overdose
...................................................................................................
17
Dosage and
Administration.....................................................................................................................
18
Pharmaceutical Information
....................................................................................................................
19
Composition:
...........................................................................................................................................
21
Availability of Dosage Forms
..........................